(Información remitida por la empresa firmante)
View original content:https://www.prnewswire.co.uk/news-releases/camurus-announces-new-phase-3-data-reinforcing-long-term-safety-and-efficacy-of-octreotide-sc-depot-cam2029-in-patients-with-acromegaly-301878210.html